Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Exclusive content, detailed data sets, and best-in-class trade insights to rewrite your portfolio for tomorrow. Nasdaq Listings Host Kristina Ayanian delves into companies' notable accomplishments, ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...